Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 13;12:90. doi: 10.1007/s40820-020-00428-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — In vivo antitumor efficacies of Eu-FBCP/PTX and Eu-s/PTX in the absence (inducing chemical ICD) and presence (boosting immuno-antitumor activity) of aPL (*p < 0.05, **p < 0.01, and ***p < 0.001). a Schematic of the experimental schedules for in vivo antitumor studies with different treatments (1: PBS, 2: free PTX, 3: Eu-s/PTX, 4: Eu-FBCP/PTX, 5: aPL, 6: Eu-s/PTX + aPL, and 7: Eu-FBCP/PTX + aPL). b, c Time profiles of tumor sizes and final weights of tumors collected from the treated mice (1–7; six mice per group). d Survival curves of the treated mice (1–7; ten mice per group). e Histopathological and immunohistochemical expression of cleaved caspase-9, cleaved caspase-3, CD8⁺, and tumor necrosis factor in tumor sections obtained from the treated mice (1–7; six mice per group). f Immune cell generation after pretreatments with PBS (normal), IgG antibody (Iso-Ab), CD4 antibody (CD4-Ab), CD8 antibody (CD8-Ab), and CD8 + CD4 antibody (CD4 + CD8-Ab) to construct an immunocompromized MC-38 tumor-bearing mouse model. g, h Time profiles of tumor sizes and final weights of tumors collected from the immunocompromized mice singly treated with Eu-FBCP/PTX + aPL or Eu-FBCP/PTX (six mice per group). i Survival curves of the immunocompromized mice singly treated with Eu-FBCP/PTX + aPL or Eu-FBCP/PTX (ten mice per group)